Nuo Therapeutics, Inc.
No SEC Form 4 filings for $AURX in the last 30 days.
See all $AURX insider activity →Nuo Therapeutics (AURX) closed a $325,000 second funding round, issuing 12% secured notes due 2028 and warrants. Total proceeds under the facility reached $2,000,000. The amendment allowed four new lenders, including a director, to join without increasing warrant coverage. The funds were secured to accelerate the second closing date and add lenders for liquidity.
Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Effective as of September 30, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Consent and Extension (the “Extension”) to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the “Loan Agreement”
Nuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99 8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633 NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth Houston, TX – August 17, 2026
Over the past 7 days, AlphAI's AI scored 2 news stories mentioning AURX (Nuo Therapeutics, Inc.). Coverage has been balanced: 0 bullish, 2 neutral, and 0 bearish.
Recent AURX coverage spans corporate actions, earnings and financial news.
The new funding improves liquidity but the small amount limits market impact.
The financing provides needed capital but is small; limited immediate price impact.
The filing combines accelerating sales momentum with improved operating loss and additional near-term liquidity, while highlighting Medicare reimbursement rulemaking that could support demand.
The announcement of a distribution agreement with Smith+Nephew is positive for Nuo Therapeutics, potentially enhancing sales channels and revenue streams.
AlphAI scores every news story that mentions AURX with an AI model for sentiment and relevance, and aggregates insider trades from Nuo Therapeutics, Inc.'s SEC EDGAR Form 4 filings. Figures refresh continuously.
Nuo Therapeutics (AURX) closed a $325,000 second funding round, issuing 12% secured notes due 2028 and warrants. Total proceeds under the facility reached $2,000,000. The amendment allowed four new lenders, including a director, to join without increasing warrant coverage. The funds were secured to accelerate the second closing date and add lenders for liquidity.
1 min readNuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Entry into a Material Definitive Agreement. Item 1.01 Entry into a Material Definitive Agreement. Effective as of September 30, 2026, Nuo Therapeutics, Inc. (the “Company”) entered into a Consent and Extension (the “Extension”) to the Amended and Restated Loan and Security Agreement dated May 29, 2026 (the “Loan Agreement”
1 min readNuo Therapeutics, Inc. (AURX) filed an SEC Form 8-K — Results of Operations and Financial Condition. Exhibit 99 8285 El Rio, Suite 190 Houston, TX 77054 Phone 833.298.6633 NUO THERAPEUTICS ANNOUNCES SECOND QUARTER 2026 FINANCIAL RESULTS AND PROVIDES BUSINESS UPDATE Differentiated Autologous PRP Remains Well-Positioned for Attractive Long-Term Growth Houston, TX – August 17, 2026
6 min readHOUSTON, April 29, 2025 ( GLOBE NEWSWIRE ) -- Nuo Therapeutics, Inc. ( OTCQB: AURX ) ( "Nuo" ) , a commercial stage medical device company pioneering leading-edge biodynamic therapies by focusing on emerging opportunities in the evolving healthcare landscape, announced it has entered into an ...
2 min read
